Samuel A. Funt

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya et al. · Journal of Clinical Oncology · 2018 · 528 citations · Full text

Higher Response Rate, Pathology, Tumor Biology +16

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

Alexandra Snyder, Tavi Nathanson, Samuel A. Funt et al. · PLoS Medicine · 2017 · 360 citations · Full text

Role of Interleukin 17 in Inflammation, Atherosclerosis, and Vascular Function in Apolipoprotein E–Deficient Mice

Meena S. Madhur, Samuel A. Funt, Li Li et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2011 · 208 citations · Full text

Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

Eugene J. Pietzak, Emily C. Zabor, Aditya Bagrodia et al. · European Urology · 2018 · 150 citations · Full text

Surgical Oncology, Urology, Genitourinary Cancer +8

Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation

Mohamed A. Saleh, William G. McMaster, Jing Wu et al. · Journal of Clinical Investigation · 2015 · 148 citations · Full text